Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies

por Numan, Syed, Faccin, Freddy
Publicado 2018

Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis

por Rosenberg, Vered, Chodick, Gabriel, Xue, Zhenyi, Faccin, Freddy, Amital, Howard
Publicado 2023

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries

por Taylor, Peter C., Gonzalez, Yuri Sanchez, Clark, Ryan, Faccin, Freddy, Howell, Oliver
Publicado 2023

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence

por Feagan, Brian G., Marabani, Mona, Wu, Jashin J., Faccin, Freddy, Spronk, Claire, Castañeda-Hernández, Gilberto
Publicado 2020

Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis

por Burmester, Gerd R., Gordon, Kenneth B., Rosenbaum, James T., Arikan, Dilek, Lau, Winnie L., Li, Peigang, Faccin, Freddy, Panaccione, Remo
Publicado 2019